Clinical Trial: Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial

U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07245316) titled 'Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial' on Aug. 20.

Brief Summary: This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received endocrine therapy.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Ductal Carcinoma in Situ of the Breast

Intervention: PROCEDURE: Avoiding surgery

Avoiding surgery in hormone-receptor positive atypical ductal hyperplasia a...